CHICAGO--(BUSINESS WIRE)--Neurowave Medical Technologies™ (“NMT”) and Alaven® Pharmaceutical (“Alaven”) have entered into an exclusive licensing agreement under which Alaven will commercialize NMT’s patented prescription neuromodulation pulse generator device for the treatment of pregnancy induced nausea and vomiting (“NVP”) in the United States.
